Target intelligence / Profile preview

Lachesis muta snake venom metalloproteinase (LmSVMP) (LmSVMP)

Target
LmSVMP
Molecular classification
Enzyme, Zinc-dependent metalloproteinase, M12B peptidase family, Reprolysin
01

Overview

Lachesis muta snake venom metalloproteinases (SVMPs) are a diverse group of zinc-dependent enzymes that constitute a major portion of the venom of the South American Bushmaster (Lachesis muta) [1, 3]. These enzymes are classified into P-I, P-II, and P-III groups based on their domain architecture, with P-III types typically being the most potent inducers of hemorrhage [2]. Biologically, SVMPs function by degrading basement membrane components of capillary blood vessels, such as type IV collagen, laminin, and fibronectin, leading to microvascular disruption and profuse bleeding [4]. They also interfere with the hemostatic system by activating or degrading clotting factors and inhibiting platelet aggregation [6]. In the context of disease, SVMPs are the primary drivers of local tissue necrosis, edema, and systemic coagulopathy observed in bushmaster envenomation [3, 5]. Therapeutic strategies focus on neutralizing these enzymes using specific antivenoms or small-molecule inhibitors like metal chelators (e.g., Unithiol) and peptidomimetic hydroxamates (e.g., Batimastat), which target the catalytic zinc site [5, 7]. These interventions are critical for preventing the rapid, often irreversible, tissue destruction and systemic hemorrhage that characterize Lachesis envenomation [8].

Other names
Bushmaster snake venom metalloproteinaseMutalysinL. muta SVMPHemorrhagic factor
02

Mechanism of action

Inhibition of enzymatic activity through chelation of the essential zinc ion (Zn2+) required for proteolytic activity or antibody-mediated neutralization of the enzyme functional domains [5, 6].

03

Biological functions

ProteolysisExtracellular matrix degradationHemorrhage inductionPro-inflammatory activityCoagulation factor cleavage
04

Disease associations

Snakebite envenomationHemorrhageTissue necrosisCoagulopathyLocal inflammation
05

Safety considerations

Risk of anaphylaxis and serum sickness associated with equine-derived antivenomsPotential for systemic toxicity or off-target inhibition of endogenous human metalloproteinases by small-molecule chelatorsRapid progression of local tissue damage
06

Interacting drugs

Lachesis muta antivenom

5 more in the full profile.

07

Biomarkers

Plasma fibrinogen concentrationProthrombin time (PT)Activated partial thromboplastin time (aPTT)Creatine kinase (CK) levels

Beyond the preview

Go deeper on Lachesis muta snake venom metalloproteinase (LmSVMP) (LmSVMP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lachesis muta snake venom metalloproteinase (LmSVMP) (LmSVMP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call